ArticleFrontiers in oncology2021
Ischemic-Free Liver Transplantation Reduces the Recurrence of Hepatocellular Carcinoma After Liver Transplantation.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- The role of machine perfusion in preventing recurrence after liver transplant for hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Oncologic Outcomes of Interventions to Decrease Allograft Ischemia-Reperfusion Injury within Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review.Current oncology (Toronto, Ont.) · 2024Pooled it
- Association between Hepatocellular Carcinoma Recurrence and Graft Size in Living Donor Liver Transplantation: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Impact of Machine Perfusion on Liver Transplantation for Hepatocellular Carcinoma.Annals of surgical oncology · 2026Article
- Simplified ischemia-free liver transplantation with continuous normothermic machine perfusion.Nature protocols · 2026Review
- Liver transplantation for hepatocellular carcinoma arising in non-cirrhotic liver: a national-wide retrospective cohort study with propensity score matching analysis in China.Hepatobiliary surgery and nutrition · 2026Article
- HCC recurrence in liver transplants treated with hypothermic oxygenated machine perfusion: An international matched cohort study.JHEP reports : innovation in hepatology · 2026Article
- Propensity Score-matched Real-world Data: HCC Recurrence Rates After DBD Liver Transplantation in Times of Machine Perfusion.Transplantation direct · 2026Article
- Outcome reporting for liver transplantation machine perfusion studies: a systematic review.EClinicalMedicine · 2026Review
- Liver Transplantation for Cancer-Current Challenges and Emerging Solutions.Journal of clinical medicine · 2025Review
- Ischemia-free liver transplantation improves long-term outcomes in a 5-year follow-up study.JHEP reports : innovation in hepatology · 2025Article
- Review
- Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver grafts.Clinical and molecular hepatology · 2024Article
- Development of a Large Animal Model of Ischemia-free Liver Transplantation in Pigs.Transplantation direct · 2024Article
- Article
- The role of ischaemia-reperfusion injury and liver regeneration in hepatic tumour recurrence.JHEP reports : innovation in hepatology · 2023Review
- FOXO1 regulates Th17 cell-mediated hepatocellular carcinoma recurrence after hepatic ischemia-reperfusion injury.Cell death & disease · 2023Article
- Impact of Hypothermic Oxygenated Machine Perfusion on Hepatocellular Carcinoma Recurrence after Liver Transplantation.Journal of personalized medicine · 2023Article
- Preservation of Mitochondrial Health in Liver Ischemia/Reperfusion Injury.Biomedicines · 2023Review
- Mitochondria and Cancer Recurrence after Liver Transplantation-What Is the Benefit of Machine Perfusion?International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemia reperfusion injury (IRI) is an adverse factor for hepatocellular carcinoma (HCC) recurrence after liver transplantation. Ischemic-free liver transplantation (IFLT) is a novel transplant procedure that can largely reduce or even prevent IRI, but the clinical relevance of IFLT and the recurrence of HCC after liver transplantation are still unknown. This retrospective study compared survival outcomes, HCC recurrence, perioperative data and IRI severity following liver transplantation (LT). 30 patients received IFLT and 196 patients received conventional liver transplantation (CLT) were chosen for the entire cohort between June 2017 and August 2020. A 1:3 propensity score matching was performed, 30 IFLT recipients and 85 matched CLT patients were enrolled in propensity-matched cohorts. An univariate and multivariate Cox regression analysis was performed, and showed surgical procedure (CLT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.